ã»ã¯ã¿:
å¥åº·ç®¡ç
æ¥ç:
蚺æãšç 究
ã¢ã¯ã»ã¹ãååŸ
ãã£ã³ã¬ã³ãžæ ªã®æ Œä»ã
ãã£ã³ã¬ã³ãžæ ªã®æ Œä»ã
ãã®æéãã©ã³ã§ã¯ãå¶éãªããµãŒãã¹ãå©çšã§ãããã¹ãŠã®æ
å ±ãå©çšå¯èœã«ãªããŸãã
ãã£ã³ã¬ã³ãžã®è©äŸ¡
ä»åŸã®ã€ãã³ã Mainz Biomed BV
ãã¹ãŠã®ã€ãã³ã
ä»åŸã®ã€ãã³ãã¯äºå®ãããŠããŸãã
èŠçŽåæ Mainz Biomed BV
ã¢ã¯ã»ã¹ãååŸ
ãã£ã³ã¬ã³ãžæ ªã®æ Œä»ã
ãã£ã³ã¬ã³ãžæ ªã®æ Œä»ã
ãã®æéãã©ã³ã§ã¯ãå¶éãªããµãŒãã¹ãå©çšã§ãããã¹ãŠã®æ
å ±ãå©çšå¯èœã«ãªããŸãã
売äžé«ãšçŽå©ç Mainz Biomed BV
ãã¹ãŠã®ãã©ã¡ãŒã¿
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. It has a collaboration agreement with Thermo Fisher Scientific Inc. for the development of colorectal cancer screening product. The company was founded in 2008 and is based in Mainz, Germany.
äœæ:
Robert Koch Strasse 50, Mainz, Germany, 55129
äŒç€Ÿå:
Mainz Biomed BV
çºè¡è
ãã£ãã«ãŒ:
MYNZ
ISIN:
NL0015000LC2
åœ:
ã¢ã¡ãªã«åè¡åœ
亀æ:
NASDAQ
é貚:
$
äžå Žæ¥:
2021-11-05
ã»ã¯ã¿:
å¥åº·ç®¡ç
æ¥ç:
蚺æãšç 究
ãµã€ã:
https://mainzbiomed.com
https://mainzbiomed.com
